Exicure, Inc. (NASDAQ:XCUR) Sees Significant Decrease in Short Interest

Exicure, Inc. (NASDAQ:XCUR) saw a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 60,402 shares, a decline of 43.8% from the July 30th total of 107,470 shares. Based on an average daily trading volume, of 43,727 shares, the days-to-cover ratio is currently 1.4 days. Currently, 2.0% of the shares of the company are short sold.

Exicure Stock Down 8.5%

NASDAQ XCUR opened at $1.29 on Friday. The firm has a market cap of $8.45 million, a P/E ratio of -0.98 and a beta of 3.65. Exicure has a 52-week low of $1.05 and a 52-week high of $9.48. The business’s 50-day moving average price is $1.70 and its 200 day moving average price is $2.94.

Exicure (NASDAQ:XCUR) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($18.60) by $18.42.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Exicure has an average rating of “Sell”.

About Exicure

Exicure is a clinical?stage biotechnology company pioneering the development of next?generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology?based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard?to?reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.